Recce Pharmaceuticals (ASX:RCE) is a world leader in synthetic polymer- antibiotics. The Company is developing a new class of broad spectrum antibiotics  

Recce Pharmaceuticals Ltd (RCE) is involved drug discovery and development business commercialising a new class of synthetic antibiotics with broad  Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United  16 Jan 2020 The Recce Pharmaceuticals Ltd (ASX:RCE) share price has had a bad week, falling 11%. On the other hand, over the last Today's RCE share price, stock chart and announcements. View dividend history, insider trades and ASX analyst consensus. 10 Feb 2020 Recce Pharmaceuticals (ASX:RCE) has announced positive data from its RECCE 327 antibiotic study in rats and dogs. 14 Feb 2020 Frequent urinary tract infection (UTI) and kidney infection sufferers may have some relief after Recce Pharmaceuticals (ASX: RCE) revealed 

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United 

Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. Our lead patented candidate, RECCE ® 327, continued to demonstrate broad spectrum antibiotic capabilities and was created to help address the urgent global health problem of antibiotic resistant superbugs. Recce Pharmaceuticals Ltd (RCE) is involved drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. Recce Pharmaceuticals Ltd (RCE) is involved drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. HotCopper has news, discussion, prices and market data on RECCE PHARMACEUTICALS LTD. Join the HotCopper ASX share market forum today for free.

Recce Pharmaceuticals Ltd, formerly Recce Limited, is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs

Recce Pharmaceuticals (ASX:RCE) is a world leader in synthetic polymer-antibiotics. The Company is developing a new class of broad spectrum antibiotics targeting superbugs. Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United States. Its lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. Recce Pharmaceuticals Ltd, formerly Recce Limited, is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. Our lead patented candidate, RECCE ® 327, continued to demonstrate broad spectrum antibiotic capabilities and was created to help address the urgent global health problem of antibiotic resistant superbugs. Recce Pharmaceuticals Ltd (RCE) is involved drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. Recce Pharmaceuticals Ltd (RCE) is involved drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs.

14 Jan 2020 Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics designed 

Recce Pharmaceuticals Ltd (RCE) is involved drug discovery and development business commercialising a new class of synthetic antibiotics with broad  Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United  16 Jan 2020 The Recce Pharmaceuticals Ltd (ASX:RCE) share price has had a bad week, falling 11%. On the other hand, over the last Today's RCE share price, stock chart and announcements. View dividend history, insider trades and ASX analyst consensus. 10 Feb 2020 Recce Pharmaceuticals (ASX:RCE) has announced positive data from its RECCE 327 antibiotic study in rats and dogs.

Recce Pharmaceuticals Ltd (ASX:RCE) has been successful with a grant application as one of five industrial partners in collaboration with 16 university and 

23 Oct 2019 SYDNEY, Australia, 23 October 2019: Recce Pharmaceuticals Ltd (ASX: RCE) ( Company), the company developing a new class of antibiotics,  14 Jan 2020 Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics designed  Recce Pharmaceuticals (ASX:RCE) is a world leader in synthetic polymer-antibiotics. The Company is developing a new class of broad spectrum antibiotics targeting superbugs. Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United States. Its lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms.

14 Feb 2020 Frequent urinary tract infection (UTI) and kidney infection sufferers may have some relief after Recce Pharmaceuticals (ASX: RCE) revealed